Results 61 to 70 of about 29,210 (297)

Activation of MYC, a bona fide client of HSP90, contributes to intrinsic ibrutinib resistance in mantle cell lymphoma

Blood Advances, 2018
: The BTK inhibitor ibrutinib has demonstrated a remarkable therapeutic effect in mantle cell lymphoma (MCL). However, approximately one-third of patients do not respond to the drug initially.
Jimmy Lee, Liang Leo Zhang, Wenjun Wu, Hui Guo, Yan Li, Madina Sukhanova, Girish Venkataraman, Hui Zhang, Mir Alikhan, Pin Lu, Ailin Guo, Natalie Galanina, Jorge Andrade, Michael L. Wang, Y. Lynn Wang   +14 more
doaj   +1 more source

Enhanced cardiomyocyte reactive oxygen species signaling promotes ibrutinib-induced atrial fibrillation

Redox Biology, 2020
Atrial fibrillation (AF) occurs in up to 11% of cancer patients treated with ibrutinib. The pathophysiology of ibrutinib promoted AF is complicated, as there are multiple interactions involved; the detailed molecular mechanisms underlying this are still ...
Xinyu Yang, Na An, Changming Zhong, Manke Guan, Yuchen Jiang, Xinye Li, Hanlai Zhang, Liqin Wang, Yanfei Ruan, Yonghong Gao, Nian Liu, Hongcai Shang, Yanwei Xing   +12 more
doaj   +1 more source

Dose reductions in patients with Waldenström macroglobulinaemia treated with ibrutinib

British Journal of Haematology, 2023
Waldenström macroglobulinaemia (WM) is characterized by the presence of a MYD88L265P mutation. This mutation promotes growth and survival of malignant cells through Bruton tyrosine kinase (BTK) activation.
S. Sarosiek, J. Gustine, C. Flynn, Carly Leventoff, M. Little, Timothy P. White, K. Meid, S. Treon, J. Castillo   +8 more
semanticscholar   +1 more source

Cost-effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia in older adults without deletion 17p

Blood Advances, 2018
: Ibrutinib is a novel oral therapy that has shown significant efficacy as initial treatment of chronic lymphocytic leukemia (CLL). It is a high-cost continuous therapy differing from other regimens that are given for much shorter courses.
James I. Barnes, Vasu Divi, Adrian Begaye, Russell Wong, Steven Coutre, Douglas K. Owens, Jeremy D. Goldhaber-Fiebert   +6 more
doaj   +1 more source

Targeting glutaminase is therapeutically effective in ibrutinib-resistant mantle cell lymphoma

Haematologica, 2022
Mantle cell lymphoma (MCL) is an incurable B-cell non-Hodgkin lymphoma characterized by frequent relapses. The development of resistance to ibrutinib therapy remains a major challenge in MCL.
Lingzhi Li, Lei Nie, Alexa Jordan, Qingsong Cai, Yang Liu, Yijing Li, Yuxuan Che, Jovanny Vargas, Zhihong Chen, Angela Leeming, Wei Wang, Yixin Yao, Michael Wang, Vivian Changying Jiang   +13 more
doaj   +1 more source

Drug Monographs: Ibrutinib and Ramucirumab [PDF]

Hospital Pharmacy, 2014
The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases.
Dominic A. Solimando, James Waddell
openaire   +3 more sources

Predictive factors and outcomes for ibrutinib in relapsed/refractory marginal zone lymphoma: a multicenter cohort study

Journal of Hematology & Oncology, 2022
Ibrutinib is effective in the treatment of relapsed/refractory (R/R) marginal zone lymphoma (MZL) with an overall response rate (ORR) of 48%. However, factors associated with response (or lack thereof) to ibrutinib in R/R MZL in clinical practice are ...
Narendranath Epperla, Qiuhong Zhao, Sayan Mullick Chowdhury, Lauren Shea, Tamara K. Moyo, Nishitha Reddy, Julia Sheets, David M. Weiner, Praveen Ramakrishnan Geethakumari, Malathi Kandarpa, Ximena Jordan Bruno, Colin Thomas, Michael C. Churnetski, Andrew Hsu, Luke Zurbriggen, Cherie Tan, Kathryn Lindsey, Joseph Maakaron, Paolo F. Caimi, Pallawi Torka, Celeste Bello, Sabarish Ayyappan, Reem Karmali, Seo-Hyun Kim, Anna Kress, Shalin Kothari, Yazeed Sawalha, Beth Christian, Kevin A. David, Irl Brian Greenwell, Murali Janakiram, Vaishalee P. Kenkre, Adam J. Olszewski, Jonathon B. Cohen, Neil Palmisiano, Elvira Umyarova, Ryan A. Wilcox, Farrukh T. Awan, Juan Pablo Alderuccio, Stefan K. Barta, Natalie S. Grover, Nilanjan Ghosh, Nancy L. Bartlett, Alex F. Herrera, Geoffrey Shouse   +44 more
doaj   +1 more source

Ibrutinib-based therapy reinvigorates CD8+ T cells compared to chemoimmunotherapy: immune monitoring from the E1912 trial

Blood, 2023
Key Points • Higher effector T-cell numbers and their rejuvenated cytotoxic function accompanies favorable clinical responses to ibrutinib-rituximab.• Enhanced CD8+ T-cell lytic synapse activity during ibrutinib-rituximab therapy can be exploited using ...
D. Papazoglou, Victoria Wang, T. Shanafelt, C. Lesnick, N. Ioannou, Giulia De Rossi, S. Herter, M. Bacac, Christian Klein, M. Tallman, Neil E. Kay, A. Ramsay   +11 more
semanticscholar   +1 more source

Lymphocytosis and ibrutinib treatment of CLL

Blood, 2014
In this issue of Blood , Woyach et al clarify that prolonged lymphocytosis is composed of biologically inert leukemic cells and does not anticipate poor outcome or relapse. Prolonged lymphocytosis may be perceived as a failure of chronic lymphocytic leukemia (CLL) treatment with ibrutinib.[1][1] ![
ROSSI, Davide, GAIDANO, Gianluca
openaire   +5 more sources

Ibrutinib Contributes to Atrial Arrhythmia through the Autophagic Degradation of Connexins by Inhibiting the PI3K-AKT-mTOR Signaling Pathway

Frontiers in Bioscience-Landmark
Background: Ibrutinib could increase the risk of atrial fibrillation (AF) in chronic lymphocytic leukemia (CLL) patients. However, the precise mechanism underlying ibrutinib-induced AF remains incompletely elucidated.
Huiyuan Qin, Bingyu Zheng, Zhiqiao Lin, Yumeng Ji, Cheng Wang, Huayuan Zhu, Chang Cui, Zidun Wang, Minglong Chen   +8 more
doaj   +1 more source